For: | Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 2004; 10(11): 1686-1687 [PMID: 15162553 DOI: 10.3748/wjg.v10.i11.1686] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i11/1686.htm |
Number | Citing Articles |
1 |
Joanna K. Law, Jaber Al Ali, P. Richard Harrigan, Christopher H. Sherlock, Kerry J. Savage, Eric M. Yoshida. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. American Journal of Hematology 2006; 81(12): 969 doi: 10.1002/ajh.20737
|
2 |
Necati Çakir, Ömer Nuri Pamuk, Hasan Ümit, Kenan Midilli. Successful Treatment with Adefovir of One Patient Whose Cryoglobulinemic Vasculitis Relapsed under Lamivudine Therapy and Who was Diagnosed to Have HBV Virologic Breakthrough with YMDD Mutations. Internal Medicine 2006; 45(21): 1213 doi: 10.2169/internalmedicine.45.1816
|
3 |
Makoto Nakamuta, Kazuhiro Kotoh, Munechika Enjoji, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Yuichi Tanabe, Jun Hayashi. Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comparative Hepatology 2007; 6(1) doi: 10.1186/1476-5926-6-3
|
4 |
Kang Mo Kim, Won-Beom Choi, Young-Suk Lim, Han-Chu Lee, Young-Hwa Chung, Young-Sang Lee, Dong-Jin Suh. Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus. Journal of Korean Medical Science 2005; 20(5): 821 doi: 10.3346/jkms.2005.20.5.821
|
5 |
Richard A. Heipertz, Jason L. Starkey, Thomas G. Miller, Jianming Hu, Harriet C. Isom. trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology 2009; 388(1): 57 doi: 10.1016/j.virol.2009.03.018
|
6 |
Ze-Xiong Chen, Shi-Jun Zhang, Shao-Xian Lao, Hong-Tao Hu, Cui-Yi Zhang, Shi-He Guan, Yan-Li Gu. He Jie Tang in the treatment of chronic hepatitis B patients. World Journal of Gastroenterology 2005; 11(42): 6638-6643 doi: 10.3748/wjg.v11.i42.6638
|
7 |
James Fung, Ching-Lung Lai, Man-Fung Yuen. Management of chronic hepatitis B in severe liver disease. World Journal of Gastroenterology 2014; 20(43): 16053-16061 doi: 10.3748/wjg.v20.i43.16053
|
8 |
Makoto Nakamuta, Shusuke Morizono, Yuichi Tanabe, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Kazuhiro Kotoh, Munechika Enjoji, Jun Hayashi: Kyushu University liver Disease Study Group. Relationship between body surface area and ALT normalization after long-term lamivudine treatment. World Journal of Gastroenterology 2005; 11(44): 6948-6953 doi: 10.3748/wjg.v11.i44.6948
|
9 |
S. Gloria Selabe, Ernest Song, Rosemary J. Burnett, M. Jeffrey Mphahlele. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. Journal of Medical Virology 2009; 81(6): 996 doi: 10.1002/jmv.21479
|
10 |
En-Qiang Chen, Fan Zeng, Ling-Yun Zhou, Hong Tang. Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure. World Journal of Gastroenterology 2015; 21(42): 11964-11973 doi: 10.3748/wjg.v21.i42.11964
|